CD19/BCMA-Targeted Universal Chimeric Antigen Receptor T Cells (UCAR-T) infusing
2026-KLS-021-02
Phase 1 small_molecule active
Quick answer
CD19/BCMA-Targeted Universal Chimeric Antigen Receptor T Cells (UCAR-T) infusing for Refractory Idiopathic Membranous Nephropathy is a Phase 1 program (small_molecule) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- First Tracks Biotherapeutics
- Indication
- Refractory Idiopathic Membranous Nephropathy
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- active